Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)

In the postpartum depression treatment market, the hospital pharmacies segment accounted for the largest share of 50.03% in 2026. Its leading position is supported by the central role hospitals play in diagnosing and initiating treatment for postpartum mental health conditions, particularly for patients requiring close clinical supervision. Hospital pharmacies ensure timely access to prescribed medications, facilitate coordinated care between psychiatrists and obstetric specialists, and maintain stringent dispensing protocols, making them the preferred distribution channel for many newly diagnosed patients.

The retail pharmacies segment is expected to register the fastest growth over the forecast period. Greater accessibility within local communities, expanding prescription fulfillment services, and increasing continuity of care following hospital discharge are encouraging patients to obtain medications through retail outlets. Broader pharmacy networks, improved patient counseling services, and the growing emphasis on long-term outpatient management of postpartum depression are further strengthening demand for this distribution channel.

Treatment Segment Analysis: Pharmacotherapy (Largest Segment) vs Hormone Therapy (Fastest-Growing Segment)

The pharmacotherapy segment held the largest share of the postpartum depression treatment market, accounting for 58.3% in 2026. Pharmacotherapy remains the cornerstone of treatment because it provides clinically established symptom management for a broad spectrum of patients experiencing moderate to severe postpartum depression. The availability of multiple therapeutic options, integration into standard treatment protocols, and widespread physician familiarity with pharmacological interventions continue to reinforce the segment’s dominant position.

Hormone therapy is anticipated to witness the fastest growth during the forecast period. Increasing recognition of the hormonal changes associated with postpartum depression has encouraged the development and adoption of therapies designed to address the underlying biological mechanisms of the condition. Continued advances in targeted treatment approaches, coupled with growing interest in personalized care strategies and expanding clinical acceptance, are expected to accelerate the uptake of hormone therapy.

Type Segment Analysis: Postpartum Anxiety (Largest Segment) vs Postpartum Psychosis (Fastest-Growing Segment)

The postpartum anxiety segment led the market with a 25.38% share in 2026. Its prominence reflects the high frequency of anxiety-related symptoms experienced after childbirth and the growing awareness among healthcare providers regarding early identification and intervention. Increased screening during prenatal and postnatal care, along with improved recognition of anxiety as a significant maternal mental health concern, has contributed to sustained demand for appropriate treatment and support services.

Holding the fastest growth trajectory, the postpartum psychosis segment is expected to expand rapidly throughout the forecast period. Although comparatively less common, the condition requires immediate medical attention because of its severe clinical presentation and potential risks to both mother and infant. Greater awareness among healthcare professionals, enhanced emergency psychiatric care pathways, and increasing emphasis on rapid diagnosis and specialized treatment are expected to support accelerated growth within this segment.